This trial aims to investigate the safety and effectiveness of durvalumab (Imfinzi) combined with chemotherapy and radiationin patients with advanced lung tumors. The main outcome that will be measured is if there are any side effects and survival without signs of disease.
The details
Duravalumab is an anti-cancer medication. It has been approved for use in patients with cancer. It uses the immune system to attack the cancer and kill it. It can be used in patients with advanced solid tumors. It is not known if durvalumab can be safely and effectively combined with chemotherapy and radiation therapy.
This trial is evaluating the safety end effectiveness of combining durvalumab with chemoradiation. The main outcome that will be measured is if there are any side effects and survival without signs of disease.
Who are they looking for?
The study is recruiting 300 patients with advanced lung tumors. The patients must have at least one solid tumor and a bodyweight 30 kg. The patients must not have been exposed to immunotherapy or irradiation before.
The patients cannot have any other types of cancers. They cannot have any other immune system issues, autoimmune conditions or infections. Cancer that has spread to the brain or spinal cord or extensive-stage small-cell lung cancer ar other exclusion criteria.
How will it work
The patients will be split up into groups based on the type of cancer they have. All patients will receive durvalumab and radiotherapy each group will receive different types of chemotherapy drugs.
The main outcome that will be measured is if there are any side effects. Response rate, survival, and duration of response will also be evaluated up to 4 years.
